Latest Conference Coverage

New data reveal vidofludimus calcium shows promise in slowing disability progression in primary progressive multiple sclerosis, warranting further trials.

At ECTRIMS 2025, experts discussed using AI-powered unstructured data processing to enhance understanding of drug efficacy, safety, and patient outcomes in multiple sclerosis. [WATCH TIME: 3 minutes]

MIL62 shows promising results in reducing relapse rates and disability progression in NMOSD, highlighting its potential as a groundbreaking treatment.

In a head-to-head phase 3 trial presented at ECTRIMS 2025, rituximab was noninferior to cladribine in preventing new or enlarging MRI lesions in relapsing-remitting multiple sclerosis.

In a late-breaking presentation at ECTRIMS 2025, findings showed that annual administration of rituximab was noninferior in efficacy to the 6-monthly treatment for relapsing-remitting multiple sclerosis.

At ECTRIMS 2025, the professor of neurology at Karolinska Institutet provided clinical insights on results from the phase 3 RIDOSE-MS trial of yearly rituximab in relapsing-remitting multiple sclerosis. [WATCH TIME: 5 minutes]

At ECTRIMS 2025, the interim chief executive officer at the Consortium of Multiple Sclerosis Centers discussed recent progress in multiple sclerosis for treatment and diagnosis. [WATCH TIME: 5 minutes]

Tiziana Life Sciences presents the design a phase 2a trial of nasal foralumab for treating nonactive secondary progressive MS at ECTRIMS 2025.

Tolebrutinib shows promise in improving quality of life for patients with nonrelapsing secondary progressive multiple sclerosis, according to recent trial findings.

Ofatumumab shows promising efficacy in treating neuromyelitis optica spectrum disorder, significantly reducing relapse rates and improving patient outcomes.

Grace Therapeutics reveals promising results for GTx-104, an innovative IV treatment for aSAH, potentially transforming patient care in neurocritical settings.

The psychiatrist and founder of the Stuttering Treatment and Research Society discussed the historical persistence of stuttering, treatment gaps, and the nuances of managing psychiatric comorbidities. [WATCH TIME: 3 minutes]

At the 2025 STARS Research & Education Conference, Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted risk factors and care interventions for stuttering in children.

Speech-language pathologist Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted the role of interdisciplinary collaboration in the management of stuttering.

The founder of the Stuttering Treatment and Research Society (STARS) discussed the unmet needs in stuttering care, current management strategies, and the mission of STARS to drive education, collaboration, and treatment development.

The founder of the Stuttering Treatment and Research Society (STARS) detailed current therapeutic strategies for stuttering, the role of dopamine pathways, and the pressing need for FDA-approved options. [WATCH TIME: 4 minutes]

A groundbreaking study reveals the connection between GLP-1 hormones and brain inflammation in neuromyelitis optica spectrum disorder, suggesting new treatment avenues.

At the 2025 STARS Research & Education Conference, the assistant professor of neurobiology and behavior at Stony Brook University discussed the current understanding of stuttering. [WATCH TIME: 5 minutes]

New research highlights daridorexant's effectiveness in improving sleep for women experiencing insomnia during menopause, showcasing significant benefits in sleep quality.

The CEO and cofounder of LSVT Global talked about how evidence-based therapies like LSVT LOUD and LSVT BIG can improve speech and movement in patients with Parkinson disease. [WATCH TIME: 5 minutes]

The director of the Adult Genetic Epilepsy Program at the University of Toronto shared “back-to-school” guidance on best practices in helping young patients with epilepsy transition to adult care.

At AHS 2025, the assistant professor of neurology at Wake Forest Baptist Atrium Health discussed clinical interventions for women with enlarged breast who experience headache. [WATCH TIME: 4 minutes]

In this seventh episode, Cohen outlined emerging Alzheimer therapies targeting amyloid, tau, and inflammation, highlighting novel antibody approaches, genetic knockdown strategies, and repurposed GLP-1 receptor agonists. Supported by Eli Lilly.

In this sixth episode, Cohen discussed aligning patient expectations with the goals of antiamyloid antibody treatment, emphasizing disease slowing, eligibility factors, and real-world satisfaction data. Supported by Eli Lilly.

A recent study reveals dual orexin receptor agonists (DORAs) show significantly lower abuse potential compared to traditional insomnia medications.

The vice president of scientific engagement at the Alzheimer's Association shared data presented at AAIC 2025 from the phase 3 U.S. POINTER study among patients at risk for dementia. [WATCH TIME: 4 minutes]

In this fifth episode, Cohen explained the types, risks, and monitoring protocols for ARIA with antiamyloid antibodies, emphasizing MRI schedules, symptom vigilance, and individualized patient safety considerations. Supported by Eli Lilly.

In this fourth episode, Sharon Cohen, MD, FRCPC, talked about key differences between lecanemab and donanemab in terms of eligibility requirements to the receive the treatment. Supported by Eli Lilly.